WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Internal Systems Limited (ISL)
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Medical
Fauna | June 15, 2022
Fauna Bio, a biotechnology company pioneering the fields of comparative, computational and translational genomics, is celebrating its fourth birthday this month with the release of Centaur, a knowledge graph that is the first of its kind to visualize the intersection between animal gene expression data and human diseases in one comprehensive map. With Centaur, Fauna Bio is able to more rapidly identify human disease indications and targets to generate new therapeutic solutions for some of the mo...
Regulatory
Braskem | April 29, 2022
Lummus Technology, a global provider of process technologies and value-driven energy solutions, announced a partnership with Braskem, the largest biopolymer producer in the world, to license green ethylene technology. Lummus and Braskem will license worldwide technology to produce green ethylene and accelerate the use of bioethanol for chemicals and plastics, supporting the industry's efforts towards a carbon neutral circular economy. We are truly excited...
Genetic Leap | March 11, 2022
Genetic Leap today announced a research collaboration agreement with Astellas Pharma, Inc. to develop novel RNA-targeted small molecule therapeutic candidates against an undisclosed oncology target. Under the terms of the agreement, Genetic Leap will deploy its platform to discover and validate RNA-targeted small molecules against an undisclosed oncology target selected by Astellas. The agreement provides Astellas with certain rights to intellectual property on candidates discover...
Regeneron | July 07, 2020
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the initiation of late-stage clinical trials evaluating REGN-COV2, Regeneron's investigational double antibody cocktail for the treatment and prevention of COVID-19. A Phase 3 trial will evaluate REGN-COV2's ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient (such as the patient's housemate), and is being run jointly with the National Institute of Allergy and Infectious ...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE